Market Overview

Oppenheimer on Serepta: Farkas Departure From FDA Is A Positive Signal For Eteplirsen Approval

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for SRPT

DateFirmActionFromTo
Sep 2017Credit SuisseMaintainsOutperform
Sep 2017BarclaysInitiates Coverage OnEqual-Weight
Jul 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (SRPT)

Loading...